Precision Medicine's Real Barrier: Execution, Not Science
Baca dalam 60 detik
- Despite $50 billion in global precision medicine funding, fewer than 10% of eligible patients receive targeted therapies due to fragmented health IT systems.
- Data silos between labs, clinics, and payers prevent real-time treatment matching.
- This execution gap costs the U.
Despite $50 billion in global precision medicine funding, fewer than 10% of eligible patients receive targeted therapies due to fragmented health IT systems. Data silos between labs, clinics, and payers prevent real-time treatment matching. This execution gap costs the U.
Leading health systems now prioritize workflow redesign over pure R&D. Intermountain Healthcare's precision oncology program cut time-to-treatment by 40% by embedding genomic counselors directly into clinical teams. Similar operational shifts could unlock 3x faster adoption rates across the industry.
The execution challenge demands new partnerships between tech vendors, payers, and providers. Companies like Tempus and Flatiron Health are building data interoperability platforms, but scale remains elusive. Without standardized reimbursement models, precision medicine will remain a science project rather than standard care.
Power Move: The next precision medicine leader won't be the one with the best sequencer—it will be the one that closes the execution gap. Expect consolidation between EHR vendors and genomic data companies within 18 months as the market pivots from discovery to delivery.
This article was edited with AI assistance for readability. Read original here.
